Fed. Circ. Urged Not To Reverse Jazz's Orange Book Delisting
Avadel CNS Pharmaceuticals LLC has asked the Federal Circuit to immediately remove patent protection for Jazz Pharmaceuticals' narcolepsy drug even though Jazz is appealing a district court order to delist a patent for the treatment, arguing...To view the full article, register now.
Already a subscriber? Click here to view full article